公开(公告)号：WO2022268745A1

公开(公告)日：2022-12-29

申请号：PCT/EP2022/066779

申请日：2022-06-21

申请人： GIVAUDAN SA

发明人： EMTER, Roger ,  NATSCH, Andreas

IPC分类号： C07K14/72 ,  G01N33/50 ,  C07K14/723 ,  C40B30/06 ,  G01N2500/10 ,  G01N33/5023

摘要： Described herein are nucleic acid constructs comprising a promoter and/or enhancer sequence operably linked to a nucleic acid sequence encoding a polypeptide, wherein said promoter and/or enhancer is inducible by an olfactory receptor, cells and populations comprising said constructs, and methods for expressing olfactory receptors and for identifying novel olfactory receptors and receptor-ligand interactions.

公开(公告)号：WO2021147977A1

公开(公告)日：2021-07-29

申请号：PCT/CN2021/073202

申请日：2021-01-22

申请人： 清华大学

发明人： 姚骏 ,  沈伟 ,  王秋文 ,  刘要南

IPC分类号： C12Q1/68 ,  A61K38/17 ,  A61P25/18 ,  A61P25/24 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356 ,  A01K67/0276 ,  A61K38/1709 ,  A61K49/0008 ,  C12N2503/02 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/47 ,  G01N2500/10 ,  G01N2800/304 ,  G01N2800/52 ,  G01N33/5008 ,  G01N33/6893

摘要： 提供了一种用于双向情感障碍的生物标志物，包括Syt7基因和/或其表达产物。还提供了Syt7基因和/或其表达产物在制备药物中的用途，所述药物用于治疗双向情感障碍。通过监控Syt7基因和/或其表达产物，可用于筛选用于治疗双向情感障碍的药物，为能够靶向Syt7分子的诊断和治疗提供帮助。

公开(公告)号：WO2021061716A2

公开(公告)日：2021-04-01

申请号：PCT/US2020/052134

申请日：2020-09-23

申请人： KANSAS STATE UNIVERSITY RESEARCH FOUNDATION ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE ,  UNIVERSITY OF NEBRASKA

发明人： PARK, Yoonseong ,  NACHMAN, Ronald ,  ANDERSON, Troy

IPC分类号： A01P7/02 ,  A61P33/14 ,  A01N63/14 ,  A01N25/32 ,  A01K47/00 ,  A61P33/00 ,  C07K7/06 ,  G01N2500/04 ,  G01N2500/10

摘要： Described herein are bee-safe acaricides that target the varroa mite-specific neuropeptidergic system regulated by proctolin, and methods of use. The acaricides comprise a peptide analog or peptidomimetic of varroa mite proctolin for selective targeting of this pest in a bee colony. The compounds are also effective against other pests, such as ticks. The peptide analog or peptidomimetic generally comprises one or two amino acid residue substitutions or insertions. Also described herein are methods of screening compounds for activity on a proctolin receptor.

公开(公告)号：WO2021260512A1

公开(公告)日：2021-12-30

申请号：PCT/IB2021/055413

申请日：2021-06-18

申请人： HIGHFLY THERAPEUTICS (HK) LIMITED

发明人： HAMZE, Moustafa Marc ,  GERARD, Annabelle Patricia Veronique

IPC分类号： G01N33/566 ,  G01N2500/04 ,  G01N2500/10

摘要： Provided herein are methods for identifying cognate pairs of a ligand species and a receptor species. The methods comprise (a) providing a set of ligand species, wherein each ligand species is represented at least one time; (b) providing a set of receptor species, wherein each receptor species is represented at least one time; (c) contacting the set of ligand species with the set of receptor species in a microreactor, wherein upon selective binding of a ligand species with a receptor species an enhanced signal is produced; (d) detecting a cognate pair of ligand species and receptor species by the production of the enhanced signal; and (a) identifying the cognate pair of ligand species and receptor species.

公开(公告)号：WO2021203142A1

公开(公告)日：2021-10-07

申请号：PCT/US2021/070350

申请日：2021-04-02

申请人： COLGATE-PALMOLIVE COMPANY

发明人： CHEN, Dandan ,  TRIVEDI, Harsh, Mahendra ,  MASTERS, James

IPC分类号： G01N33/566 ,  A61Q11/00 ,  A61K8/27 ,  A61K8/365 ,  G01N2500/04 ,  G01N2500/10

摘要： Methods for identifying a composition that neutralizes toxicity of a lipopolysaccharide are disclosed. The methods comprise comparing the amount of cytokine and/or prostaglandin E2 secreted by cells that have Toll-like receptors activated by a lipopolysaccharide in the presence or absence of a test composition. Methods of neutralizing toxicity of a lipopolysaccharide in an individual's oral cavity using compositions identified neutralizing toxicity of a lipopolysaccharide are also disclosed. Method of neutralizing toxicity of a lipopolysaccharide in an individual's oral cavity using oral care compositions that comprise combinations of zinc oxide and zinc citrate are also disclosed.

公开(公告)号：WO2021148681A1

公开(公告)日：2021-07-29

申请号：PCT/EP2021/051645

申请日：2021-01-25

申请人： MEDIZINISCHE UNIVERSITÄT WIEN ,  REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： OGRIS, Egon ,  NARLA, Goutham

IPC分类号： C07K16/40 ,  G01N33/00 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/92 ,  G01N2333/916 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/042 ,  G01N2800/28 ,  G01N2800/325 ,  G01N2800/52 ,  G01N33/573 ,  G01N33/57434

摘要： The present invention relates to an antibody specifically binding the carboxymethylated catalytic subunit of protein phosphatase 2A (PP2Ac). Also provided are diagnostic uses of said antibody and screening methods employing the inventive antibody.

公开(公告)号：WO2023283537A2

公开(公告)日：2023-01-12

申请号：PCT/US2022/073378

申请日：2022-07-01

申请人： INSTITUTE FOR SYSTEMS BIOLOGY ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： XUE, Min ,  WEI, Wei ,  GUO, Zhili ,  CHENG, Hanjun ,  LI, Zhonghan

IPC分类号： G01N33/547 ,  B01J19/00 ,  G01N21/64 ,  G01N33/533 ,  A61P35/00 ,  C12N5/00 ,  G01N2500/10 ,  G01N33/542 ,  G01N33/54353

摘要： A chemical approach is provided to profile uptake of compounds in cells, alone or in combination with other analytical techniques. The disclosure is particularly well suited for detecting cellular uptake of metabolites such as fatty acids. The disclosure can be carried out, applied in solution or on a surface, in bulk or on single cells, and is compatible with one or more additional techniques such as protein analysis. The disclosure is exemplified by probing fatty acid influx alone and in combination with proteomics analysis on a single-cell barcode chip to identify a combination therapy for inhibiting fatty acid metabolism and treating cancer.

公开(公告)号：WO2022204564A2

公开(公告)日：2022-09-29

申请号：PCT/US2022/022030

申请日：2022-03-25

申请人： IOVANCE BIOTHERAPEUTICS, INC.

发明人： SIMPSON-ABELSON, Michelle, R. ,  FRIGAULT, Matthew, J. ,  ROTHBAUM, Wayne, P. ,  WEISER, Michael

IPC分类号： C12N5/0783 ,  A61K35/17 ,  G01N33/50 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/55533 ,  A61K38/2013 ,  A61K39/0011 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2502/1114 ,  C12N2502/1157 ,  C12N2502/30 ,  C12N2503/00 ,  C12N5/0638 ,  G01N2333/57 ,  G01N2500/10 ,  G01N33/5008 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/6866

摘要： The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

公开(公告)号：WO2022188817A1

公开(公告)日：2022-09-15

申请号：PCT/CN2022/079987

申请日：2022-03-09

申请人： BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

发明人： ZHANG, Rufeng ,  SHANG, Chengzhang ,  NIE, Yanhui

IPC分类号： G01N33/50 ,  C12N15/09 ,  C07K16/28 ,  A01K67/027 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0362 ,  A01K67/0278 ,  A61K49/0008 ,  C07K14/723 ,  C12N15/8509 ,  G01N2500/10 ,  G01N2800/042 ,  G01N2800/044 ,  G01N33/5008

摘要： Genetically modified non-human animals that express a human or chimeric (e.g., humanized) GCGR, and methods of use thereof.

公开(公告)号：WO2022012198A1

公开(公告)日：2022-01-20

申请号：PCT/CN2021/097813

申请日：2021-06-02

申请人： 广州泛恩生物科技有限公司

发明人： 刘海平 ,  李翔 ,  李游 ,  卞超超

IPC分类号： C12N5/10 ,  A61K39/00 ,  A61P35/00 ,  C12Q1/02 ,  A61K2039/5156 ,  A61K39/001111 ,  C12N2503/02 ,  C12N2510/00 ,  C12N5/0636 ,  G01N2333/7051 ,  G01N2500/10 ,  G01N33/505

摘要： 本发明提供了一种用于杀伤肿瘤的TCR-T细胞，其特征在于，所述TCR-T细胞为携带有识别肿瘤抗原TCR的T细胞，所述TCR-T细胞中的TCR来源于以下中的任意一个或多个T细胞：1)在肿瘤中表达TNFRSF18、CXCL13、TNFRSF4、TNFSF8、ENTPD1、ACP5、LAYN、TNFRSF9、CTLA4、CD200、TIGIT这些基因中的一个或多个的CD4T细胞；2)在肿瘤中表达TNFRSF18、CXCL13、CXCR6、GALNT2、ENTPD1、ACP5、HAVCR2、LAYN、TNFRSF9、CTLA4、CD109这些基因中的一个或多个的CD8T细胞。本发明的TCR-T细胞能够有效应用于治疗肿瘤，特别是免疫治疗。